Virus Protease
Viral proteases are enzymes encoded by the genetic material (DNA or RNA) of viral pathogens. Viral proteases catalyze the cleavage of specific peptide bonds in viral polyprotein precursors or in cellular proteins. Viral proteases may use different catalytic mechanisms involving either serine, cysteine or aspartic acid residues to attack the scissile peptide bond. Selective recognition of these sequence patterns by a complementary substrate binding site of the enzyme ensures a high degree of specific recognition and cleavage.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the cause of the respiratory illness coronavirus disease 2019 (COVID-19). Initial spike protein priming by transmembrane protease, serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2. After a SARS-CoV-2 virion attaches to a target cell, the cell's protease TMPRSS2 cuts open the spike protein of the virus, exposing a fusion peptide.
All Product Categories
-
Virus Protease Related Products (404)
Related Products (404)
-
Antibodies (1)
-
Y-U0-S
0 ImagesCat. No.: HY-189662Y-U0-S is a potent inhibitor of the coronavirus main protease (Mpro) and host cathepsins. The IC50 values of Y-U0-S against SARS-CoV-2 Mpro, SARS-CoV Mpro, Cathepsin B, and Cathepsin L are 0.81, 1.14, 0.86, and 21.13 μM, respectively. Y-U0-S exhibits broad-spectrum anti-coronavirus activity, with an EC50 of 0.22 μM against wild-type SARS-CoV-2. Y-U0-S forms an irreversible covalent bond with the catalytic site C145 of Mpro through its aldehyde warhead, and by optimizing multi-site occupancy of the scaffold to engage conserved residues, it effectively blocks enzyme activity and inhibits viral replication. Y-U0-S can be used for research on COVID-19.
-
EBOV-IN-10
0 ImagesCat. No.: HY-168047CAS No.: 3040400-51-6EBOV-IN-10 is an orally active Ebola virus (EBOV) inhibitor with an EC50 value of 0.19 μM.
-
Y-U0-R
0 ImagesCat. No.: HY-189663Y-U0-R is a potent covalent inhibitor of coronavirus main protease (Mpro), with IC50 values of 0.22 and 0.25 μM against SARS-CoV-2 Mpro and SARS-CoV Mpro, respectively. Y-U0-R exhibits broad-spectrum anti-coronavirus activity, with an EC50 of 0.47 µM against SARS-CoV-2. Y-U0-R forms a stable hemithioacetal covalent bond with the catalytic residue C145 through its aldehyde warhead, and occupies multiple active subsites and residue networks, resulting in time-dependent irreversible inhibition of enzymatic activity. Y-U0-R can be used for research on COVID-19 and SARS-CoV-2 infection.
-
BFC204
0 ImagesCat. No.: HY-180516CAS No.: 154419-89-3BFC204 is a SARS-CoV-2 Mpro inhibitor with a kinact/Ki value of 619 mol/s.
-
(+)-Adlumidine
0 Images(+)-Adlumidine (Adlumidine) is an isoquinoline alkaloid. (+)-Adlumidine efficiently binds to two key targets of SARS-CoV-2, Mpro and RBD, with IC50 values of 953.86 nM and 9.48 μM, respectively. (+)-Adlumidine exerts significant positive inotropic effects and certain positive chronotropic effects on cultured mouse embryonic cardiomyocytes. (+)-Adlumidine can be used for research on cardiovascular-related diseases and SARS-CoV-2 infection.
-
SARS-CoV-2 3CLpro-IN-38
0 ImagesCat. No.: HY-184269SARS-CoV-2 3CLpro-IN-38 is a 3CLpro inhibitor with an IC50 of 0.34 μM against SARS-CoV-2 3CLpro and an IC50 of 0.12 μM against MERS-CoV 3CLpro. SARS-CoV-2 3CLpro-IN-38 inhibits recombinant Cathepsin L with an IC50 of 5.23 nM. SARS-CoV-2 3CLpro-IN-38 inhibits cysteine proteases essential for the replication of SARS-CoV-2 and MERS-CoV, suppresses host cysteine proteases involved in coronavirus entry, blocks viral entry, and inhibits viral replication. SARS-CoV-2 3CLpro-IN-38 can be used in the research of COVID-19.
-
Anti-infective agent 10
0 ImagesCat. No.: HY-172230CAS No.: 1132936-19-6Anti-infective agent 10 (Compound Example 30) is a ns5b polymerase inhibitor that can be used as an anti-HCV agent.
-
SARS-CoV-2 Mpro-IN-57
0 ImagesCat. No.: HY-182754CAS No.: 3031240-80-6SARS-CoV-2 Mpro-IN-57 is an irreversible SARS-CoV-2 main protease inhibitor with an IC50 of 0.41 μM and a Kd of 247.37 nM. SARS-CoV-2 Mpro-IN-57 forms a covalent bond with the key amino acid residue Cys145 in SARS-CoV-2 main protease via its -CN group. SARS-CoV-2 Mpro-IN-57 can be used for the research of COVID-19.
-
Plerixafor octahydrochloride (Standard)
0 ImagesSynonyms: AMD3100 octahydrochloride (Standard); JM3100 octahydrochloride (Standard); SID791 octahydrochloride (Standard)Plerixafor (octahydrochloride) (Standard) is the analytical standard of Plerixafor (octahydrochloride). This product is intended for research and analytical applications. Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
-
GC376 sodium (Standard)
0 ImagesGC376 (sodium) (Standard) is the analytical standard of GC376 (sodium) (HY-100721). This product is intended for research and analytical applications. GC376 sodium is a 3CLpro inhibitor; inhibits the replication of viruses TGEV, FIPV and PTV with IC50 values of 0.15, 0.2 and 0.15 μM, respectively.
-
Bardoxolone methyl (Standard)
0 ImagesCat. No.: HY-13324RCAS No.: 218600-53-4Synonyms: RTA 402 (Standard); NSC 713200 (Standard); CDDO Methyl ester (Standard)Bardoxolone methyl (Standard) is the analytical standard of Bardoxolone methyl (HY-13324). This product is intended for research and analytical applications. Bardoxolone methyl (RTA 402) is an orally active and blood-brain-barrier-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC50 value of 0.29 μM. Bardoxolone methyl increases levels of pNrf2 and HO-1, inhibits inflammatory mediators like pNFκB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic Kidney disease (CKd).
-
SARS-CoV-2 Mpro-IN-29
0 ImagesCat. No.: HY-159911SARS-CoV-2 Mpro-IN-29 (Compound 7) is an inhibitor of the SARS-CoV-2 main protease (Mpro) with an IC50 of 310 nM and an EC50 of 0.5 μM in Vero cells. SARS-CoV-2 Mpro-IN-29 binds to the active site of Mpro, blocking the cleavage of viral polyproteins, showing significant antiviral activity and enhanced metabolic function. SARS-CoV-2 Mpro-IN-29 holds potential for research on SARS-CoV-2 antiviral agents.
-
7-Hydroxyflavone (Standard)
0 Images7-Hydroxyflavone (Standard) is the analytical standard of 7-Hydroxyflavone. This product is intended for research and analytical applications. 7-Hydroxyflavone is a flavonoid isolated from Clerodendrum phlomidis, with anti-inflammatory activity. 7-Hydroxyflavone protects renal cells from nicotine (NIC)-associated cytotoxicity via the ERK/Nrf2/HO-1 pathway. 7-Hydroxyflavone inhibits PKM2 with an IC50 of 2.12 μM. 7-Hydroxyflavone inhibits COX-2 and 5-LOX with IC50 of 27 µg/mL and 33 µg/mL. 7-Hydroxyflavone is orally active.
-
PROTAC SARS-CoV-2 Mpro degrader-7
0 ImagesCat. No.: HY-181193PROTAC SARS-CoV-2 Mpro degrader-7 is a SARS-CoV-2 main protease (Mpro) PROTAC degrader with a DC50 of 0.985 μM. PROTAC SARS-CoV-2 Mpro degrader-7 promotes K48-linked polyubiquitination of SARS-CoV-2 Mpro, leading to proteasome-dependent degradation via the ubiquitin-proteasome system.PROTAC SARS-CoV-2 Mpro degrader-7 forms a ternary complex with SARS-CoV-2 Mpro and CRBN E3 ubiquitin ligase to enable viral protease ubiquitination.PROTAC SARS-CoV-2 Mpro degrader-7 exhibits a high selectivity index, and induces dose-dependent degradation of SARS-CoV-2 Mpro in stable cells expressing the viral protease.PROTAC SARS-CoV-2 Mpro degrader-7 can be used for the research of COVID-19.
-
SARS-CoV-2 Mpro-IN-34
0 ImagesCat. No.: HY-159961CAS No.: 3061154-57-9SARS-CoV-2 Mpro-IN-34 (Compound 26) is an inhibitor for SARS-CoV-2 Mpro with an IC50 of 6 nM. SARS-CoV-2 Mpro-IN-34 exhibits inhibitory efficacy against OC43 Mpro with an IC50 of 33 nM. SARS-CoV-2 Mpro-IN-34 exhibits antiviral activity in SARS-CoV-2 infected Vero E6 cell with an EC50 of 0.103 μM.
-
SARS-CoV-2 Mpro-IN-39
0 ImagesCat. No.: HY-173362SARS-CoV-2 Mpro-IN-39 (Compound 9d) is an inhibitor of the main protease (Mpro) of SARS-CoV-2, with an IC50 value of 5.94 µM, an EC50 value of 9.33 µM for inhibiting the replication of SARS-CoV-2 in Vero cells, and a cytotoxicity CC50 value of 289.63 µM. SARS-CoV-2 Mpro-IN-39 can be used in the research of the anti-COVID-19 field.
